Audrey Fuks
Psychiatric/Mental Health · Sioux Falls, SDNPI 1538807581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations.
Across 127 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$349
- Teva Pharmaceuticals USA, Inc.$297
- Alkermes, Inc.$262
- AbbVie$206
- Neurocrine Biosciences, Inc.$196
- E.r. Squibb & Sons, L.L.C.$158
- plus $415 from 6 others
What the payments were for
- Food & beverage$1,72892%
- Education$1558%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 28 | $349 |
| Teva Pharmaceuticals USA, Inc. | 12 | $297 |
| Alkermes, Inc. | 11 | $262 |
| AbbVie | 34 | $206 |
| Neurocrine Biosciences, Inc. | 12 | $196 |
| E.r. Squibb & Sons, L.L.C. | 5 | $158 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $152 |
| Vanda Pharmaceuticals Inc. | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| Axsome Therapeutics, Inc. | 3 | $41 |
| Lundbeck LLC | 2 | $34 |
| Corium, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$122
How this compares
$1,883 in reported general payments places this provider in the 80th percentile of 77 psychiatric/mental health providers in South Dakota.
See all psychiatric/mental health providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 227 | $776,591 |
| IngrezzaValbenazine Tosylate | 34 | $280,268 |
| AristadaAripiprazole Lauroxil | 39 | $129,172 |
| VraylarCariprazine Hcl | 102 | $124,530 |
| RexultiBrexpiprazole | 78 | $71,428 |
| CaplytaLumateperone Tosylate | 52 | $52,636 |
| Clozapine OdtClozapine | 34 | $21,564 |
| VivitrolNaltrexone Microspheres | 11 | $17,761 |
| Clozapine | 390 | $17,400 |
| Lurasidone Hcl | 73 | $15,164 |
| Paliperidone ErPaliperidone | 53 | $10,864 |
| BelsomraSuvorexant | 38 | $10,105 |
| Clomipramine Hcl | 18 | $7,877 |
| QuviviqDaridorexant Hcl | 12 | $5,479 |
| Divalproex Sodium ErDivalproex Sodium | 40 | $5,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $349 | $776,591227 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $196 | $280,26834 claims |
| Alkermes, Inc.Aristada, Vivitrol | $262 | $146,93350 claims |
| AbbVieVraylar | $206 | $124,530102 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $67 | $71,42878 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $152 | $52,63652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 psychiatric/mental health providers in South Dakota.
Other psychiatric/mental health in Sioux Falls
- Nichole JohnsonSioux Falls$5K
- Andria PetersenSioux Falls$5K
- Holly AhlersSioux Falls$4K
- Afton ArtzSioux Falls$2K
- Marie JamesonSioux Falls$761
- Veronica SherwoodSioux Falls$756
- Taylor RobertsSioux Falls$717
- Kaitlyn WalkerSioux Falls$574
- Hannah OttenSioux Falls$376
- Garneth KuiperSioux Falls$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.